Johnson & Johnson, the US healthcare group, will in future take more long-term minority stakes and forge alliances with rival pharmaceuticals companies in an effort to share the rising costs and risks of drug development.

William Weldon, chief executive, told the Financial Times: “The cost of developing compounds has become so high and become so risky that we are looking to share the risks and opportunities and find more and more partnerships.”